What We’re Reading: Alabama IVF Ruling; UnitedHealth Antitrust Probe; Food as Medicine Initiative
February 28th 2024Survey highlights widespread opposition to Alabama's law restricting in vitro fertilization (IVF) access; investigation focuses on potential anticompetitive practices; Medicare weighs options for implementing a new program to deliver healthy meals to seniors with chronic conditions.
COA Asks CMS to Resolve Express Scripts’ “Underwater” Payments Following End of DIR Fees
February 27th 2024The Community Oncology Alliance (COA), which represents independent cancer care practices, has asked CMS to act following a dramatic drop in reimbursements from Express Scripts, Inc. effective January 1, 2024.
What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response
February 26th 2024Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
What We’re Reading: Weight Loss Drug Coverage; COVID Vaccine Potential AEs; Shifting Medicaid Policy
February 20th 2024Insurers grapple with expanding overage for weight loss medications; a new analysis reveals a potential correlation between COVID-19 vaccinations and various adverse effects (AEs); reshaping Medicaid programs remains an ongoing debate about ensuring health care access.
Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG
February 15th 2024Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
What We’re Reading: Medicare Lawsuit Dismissed; COVID Isolation Guidelines; Millions Have Long COVID
February 13th 2024A ruling against Pharmaceutical Research and Manufacturers of America marks victory for efforts to lower health care costs; new guidelines align with flu and respiratory syncytial virus protocols; children and pregnant individuals are burdened with long-term health symptoms in the aftermath of COVID-19.
Research Letter Shines Spotlight on Low Screening for HF Among Patients With T1D
February 10th 2024The findings follow endorsement of the screening measure from the American Diabetes Association, which recommended the practice to identify patients who have type 1 diabetes (T1D) who could benefit from targeted strategies to prevent symptomatic heart failure (HF).